Related Experiment Videos
Adenosine A2A receptor agonists as anti-inflammatory agents
1Cardiovascular Research Center, University of Virginia Health Sciences Center, MR-5 Room 1314, 415 Lane Rd, Box 801394, Charlottesville, VA 22908, USA. gws3u@virginia.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|February 5, 2004
Summary
Endogenous adenosine, acting via A2A adenosine receptors (ARs), reduces inflammation by inhibiting immune cell activation. Synthetic A2A AR agonists show promise for treating inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
- Molecular Biology
Background:
- Stressed or injured tissues release adenosine, a key regulator of inflammatory responses.
- Adenosine exerts anti-inflammatory effects by binding to A2A adenosine receptors (ARs).
- This interaction inhibits the activation of platelets, leukocytes, and endothelial cells, reducing tissue damage.
Purpose of the Study:
- To review the therapeutic potential of A2A adenosine receptor (AR) agonists.
- To discuss the mechanisms underlying A2A AR agonist action in inflammatory conditions.
- To explore considerations for the design of synthetic A2A AR agonists.
Main Methods:
- Review of preclinical data on A2A AR agonists.
- Analysis of adenosine's signaling pathways.
- Discussion of disease targets and drug design principles.
Main Results:
- Adenosine reduces the expression of adhesion molecules and the release of pro-inflammatory mediators like reactive oxygen species, elastase, and tumor necrosis factor-alpha.
- Synthetic A2A AR agonists are in preclinical development for conditions such as allergic inflammation, ischemia-reperfusion injury, sepsis, and autoimmune diseases.
- A2A AR agonists demonstrate a broad potential for modulating immune responses and mitigating tissue injury.
Conclusions:
- A2A AR agonists represent a promising therapeutic strategy for a range of inflammatory and autoimmune diseases.
- Understanding the mechanisms of A2A AR action is crucial for optimizing agonist design and efficacy.
- Further preclinical development is warranted to translate the potential of A2A AR agonists into clinical applications.